Infinitopes Secures $35.1M to Advance Precision Cancer Vaccine
January 24, 2026, 3:54 pm
Location: United Kingdom, England, London
Employees: 1001-5000
Founded date: 1902
Location: United Kingdom, England, London
Employees: 1001-5000
Founded date: 1911
Total raised: $1.46M
Infinitopes, an Oxford-based biotechnology firm, has significantly expanded its seed financing. The company secured an additional $15.4 million. This latest infusion brings total seed funding to $35.1 million. The capital directly targets clinical acceleration. Its lead precision cancer vaccine candidate, ITOP1, will now progress. It enters first-in-human Phase I/IIa clinical trials. This marks a pivotal moment in cancer research.
The expanded financing round was co-led. Octopus Ventures, an existing investor, participated. New investor Amplify Bio also took a leading role. Amplify Bio's involvement introduces a new U.S. presence to Infinitopes' investor base. This expands its global reach. Further participation came from new investor Macmillan Cancer Support. This highlights a focus on patient care. Existing backers Cancer Research Horizons and Manta Ray Ventures also contributed. The diverse investor syndicate strengthens Infinitopes' strategic position. It underscores confidence in the company's innovative platform.
Infinitopes is now poised to launch a crucial clinical study. The trial is named VISTA. It is a Phase I/IIa program. This study will be double-blind and randomized. It will include a placebo-controlled arm. The primary objective is to evaluate ITOP1. The vaccine aims to prevent recurrence in oesophageal cancer. This applies to patients following surgical resection. Oesophageal cancer carries a high unmet medical need. Recurrence remains a significant challenge. ITOP1 addresses this critical gap directly.
The VISTA trial will run across multiple sites. Several UK NHS university cancer centers will host the study. This provides a robust clinical environment. Researchers will assess ITOP1's safety. They will also look for early signals of activity. This early data is crucial. It seeks to establish proof of concept. The vaccine operates as an off-the-shelf platform. Its development is informed by advanced AI and machine learning.
Infinitopes leverages two world-leading platforms. One is precision target discovery. The other is high-efficiency vector delivery systems. These combined technologies drive its vaccine development. The goal is to generate immunologically durable vaccines. These target multiple solid tumor indications. ITOP1 embodies this integrated approach. It promises a new era in oncology treatment.
The company's foundations are strong. It receives support from Cancer Research UK. The University of Oxford also backs its efforts. Infinitopes is based in the Oxford ecosystem. It operates from Oxford University’s BioEscalator innovation accelerator. It is currently the largest tenant. This proximity fosters innovation and collaboration.
Infinitopes has received prior regulatory recognition. It secured an Innovative Licensing and Access Pathway (ILAP) innovation passport. This came from the UK Medicines and Healthcare products Regulatory Agency (MHRA) in 2022. This passport streamlines regulatory processes. It accelerates access to innovative medicines. The company also received two maximum-size non-dilutive awards. Innovate UK provided these awards. They included a Cancer Therapeutics Award in 2022. A Future Economy Investor Partnership award followed in 2023. These accolades underscore the company's scientific rigor and potential impact.
The expanded seed round is highly strategic. Amplify Bio noted momentum in the broader cancer vaccine field. They cited Infinitopes’ immunomics profiling. Its vector approach and clinical strategy were key differentiators. Macmillan Cancer Support's involvement is also significant. It brings a patient-care organization into the financing syndicate. This ensures patient perspective remains central.
Infinitopes has built comprehensive internal capabilities. These span critical areas. They include antigen discovery and immunology. Vaccinology and oncology expertise are present. Biomanufacturing capabilities are robust. The company manages clinical trials and regulatory functions in-house. This integrated model provides efficiency and control. It ensures rapid advancement of its pipeline.
Since its incorporation, Infinitopes has raised substantial capital. The total stands at over $35.1 million. This funding comes from a group of sector-focused investors. These include Cancer Research Institute, Kindred Capital, Martlet, Meltwind, Saras Capital, Wilbe, and Fundación CRIS Contra el Cáncer. The company has also grown its team. It started with three academic co-founders. Now it employs roughly 20 full-time equivalents. This growth reflects its expanding ambitions.
The funding is primarily earmarked for the VISTA trial. It will support execution and data generation. Beyond ITOP1, the funding advances Infinitopes’ broader platform ambitions. The underlying technology is applicable to multiple solid tumor settings. The near-term focus remains clear. Demonstrate clinical feasibility and early efficacy signals. Oesophageal cancer provides the initial clinical proof.
Early findings are anticipated. Infinitopes expects to share results at major conferences later this year. This will offer crucial insights into ITOP1's performance. The company aims to lead innovative medicine development. It targets cancers with significant unmet medical needs. This funding marks a critical step towards redefining immunotherapy. It offers new hope for patients worldwide. Infinitopes pushes the boundaries of precision oncology. Its platform holds transformative potential.
The expanded financing round was co-led. Octopus Ventures, an existing investor, participated. New investor Amplify Bio also took a leading role. Amplify Bio's involvement introduces a new U.S. presence to Infinitopes' investor base. This expands its global reach. Further participation came from new investor Macmillan Cancer Support. This highlights a focus on patient care. Existing backers Cancer Research Horizons and Manta Ray Ventures also contributed. The diverse investor syndicate strengthens Infinitopes' strategic position. It underscores confidence in the company's innovative platform.
Infinitopes is now poised to launch a crucial clinical study. The trial is named VISTA. It is a Phase I/IIa program. This study will be double-blind and randomized. It will include a placebo-controlled arm. The primary objective is to evaluate ITOP1. The vaccine aims to prevent recurrence in oesophageal cancer. This applies to patients following surgical resection. Oesophageal cancer carries a high unmet medical need. Recurrence remains a significant challenge. ITOP1 addresses this critical gap directly.
The VISTA trial will run across multiple sites. Several UK NHS university cancer centers will host the study. This provides a robust clinical environment. Researchers will assess ITOP1's safety. They will also look for early signals of activity. This early data is crucial. It seeks to establish proof of concept. The vaccine operates as an off-the-shelf platform. Its development is informed by advanced AI and machine learning.
Infinitopes leverages two world-leading platforms. One is precision target discovery. The other is high-efficiency vector delivery systems. These combined technologies drive its vaccine development. The goal is to generate immunologically durable vaccines. These target multiple solid tumor indications. ITOP1 embodies this integrated approach. It promises a new era in oncology treatment.
The company's foundations are strong. It receives support from Cancer Research UK. The University of Oxford also backs its efforts. Infinitopes is based in the Oxford ecosystem. It operates from Oxford University’s BioEscalator innovation accelerator. It is currently the largest tenant. This proximity fosters innovation and collaboration.
Infinitopes has received prior regulatory recognition. It secured an Innovative Licensing and Access Pathway (ILAP) innovation passport. This came from the UK Medicines and Healthcare products Regulatory Agency (MHRA) in 2022. This passport streamlines regulatory processes. It accelerates access to innovative medicines. The company also received two maximum-size non-dilutive awards. Innovate UK provided these awards. They included a Cancer Therapeutics Award in 2022. A Future Economy Investor Partnership award followed in 2023. These accolades underscore the company's scientific rigor and potential impact.
The expanded seed round is highly strategic. Amplify Bio noted momentum in the broader cancer vaccine field. They cited Infinitopes’ immunomics profiling. Its vector approach and clinical strategy were key differentiators. Macmillan Cancer Support's involvement is also significant. It brings a patient-care organization into the financing syndicate. This ensures patient perspective remains central.
Infinitopes has built comprehensive internal capabilities. These span critical areas. They include antigen discovery and immunology. Vaccinology and oncology expertise are present. Biomanufacturing capabilities are robust. The company manages clinical trials and regulatory functions in-house. This integrated model provides efficiency and control. It ensures rapid advancement of its pipeline.
Since its incorporation, Infinitopes has raised substantial capital. The total stands at over $35.1 million. This funding comes from a group of sector-focused investors. These include Cancer Research Institute, Kindred Capital, Martlet, Meltwind, Saras Capital, Wilbe, and Fundación CRIS Contra el Cáncer. The company has also grown its team. It started with three academic co-founders. Now it employs roughly 20 full-time equivalents. This growth reflects its expanding ambitions.
The funding is primarily earmarked for the VISTA trial. It will support execution and data generation. Beyond ITOP1, the funding advances Infinitopes’ broader platform ambitions. The underlying technology is applicable to multiple solid tumor settings. The near-term focus remains clear. Demonstrate clinical feasibility and early efficacy signals. Oesophageal cancer provides the initial clinical proof.
Early findings are anticipated. Infinitopes expects to share results at major conferences later this year. This will offer crucial insights into ITOP1's performance. The company aims to lead innovative medicine development. It targets cancers with significant unmet medical needs. This funding marks a critical step towards redefining immunotherapy. It offers new hope for patients worldwide. Infinitopes pushes the boundaries of precision oncology. Its platform holds transformative potential.